ArticleScientific reports2026
6-gingerol attenuates renal interstitial fibrosis by downregulating PI3K/Akt/mTOR signaling pathway in unilateral ureteral obstruction rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Renal interstitial fibrosis is the predominant cause of end-stage renal disease. Oxidative stress and an increased PI3K/Akt/mTOR pathway play a key role in the development of renal interstitial fibrosis caused by ureteral obstruction. 6-gingerol (6-G) is known to have a natural antioxidant effect; however, the effect of 6-G on progressive renal fibrosis due to ureteral obstruction has not been fully elucidated. The aim of the study is to evaluate the antifibrotic effect of 6-G and characterize the underlying mechanism of its action on unilateral ureteral obstruction (UUO) rats. Male Sprague-Dawley rats underwent UUO via double ligation of the left ureter for a duration of 14 days. Sham rats underwent identical treatment, with the exception of the absence of double ligation. The levels of phosphorylated PI3K/Akt/mTOR in the kidney were assessed by semiquantitative immunoblotting, while the gene expressions of TGF-β1 and α-SMA were evaluated through qRT-PCR. Oxidative stress parameters were evaluated with an ELISA kit and spectrophotometer, while histopathological assessment was conducted through Masson's trichrome, hematoxylin and eosin (HE), and immunohistochemical analysis of collagen type III. In comparison to UUO rats, renal fibrosis and collagen type III deposition were diminished, and the phosphorylation of PI3K/Akt/mTOR was reduced in rats treated with 6-G. 6-G also reduced the expression of TGF-β1 and α-SMA genes in obstructed kidneys. In comparison to UUO rats, rats administered with 6-G exhibited elevated activities of glutathione peroxidase and decreased levels of malondialdehyde. The findings suggest that 6-G is a potential therapeutic agent for renal interstitial fibrosis, with its antifibrotic actions perhaps facilitated by the enhanced activity of the PI3K/Akt/mTOR pathways and decreased oxidative stress in UUO rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.